Jolanda Paolini
Pfizer (Italy) · 39 works · 5,945 citations · h-index 19
Top works
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
- First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer
- The minimal effective exemestane dose for endocrine activity in advanced breast cancer
- Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
- Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc)
- Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study
- Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk
- Radiographic progression by Prostate Cancer Working Group ( PCWG )‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
- Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.
- Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).
- Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies